<div id="readability-page-1"><p>Cwm LLC lessened its stake in shares of  QuidelOrtho Corporation (NASDAQ:QDEL - Free Report) by 82.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 6,765 shares of the company's stock after selling 32,785 shares during the period. Cwm LLC's holdings in QuidelOrtho were worth $199,000 at the end of the most recent quarter.</p><ul><li>Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11</li></ul><p>Several other institutional investors and hedge funds also recently bought and sold shares of the company. Allworth Financial LP raised its stake in shares of  QuidelOrtho by 2,460.9% in the second quarter. Allworth Financial LP now owns 1,178 shares of the company's stock valued at $34,000 after acquiring an additional 1,132 shares during the period.  Blue Trust Inc. raised its holdings in shares of  QuidelOrtho by 46.4% in the second quarter. Blue Trust Inc. now owns 1,967 shares of the company's stock worth $57,000 after buying an additional 623 shares during the period.  Tableaux LLC bought a new stake in shares of  QuidelOrtho during the 2nd quarter worth approximately $93,000.  EverSource Wealth Advisors LLC boosted its holdings in  QuidelOrtho by 250.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company's stock valued at $93,000 after acquiring an additional 2,309 shares during the period.  Finally, Osaic Holdings Inc. increased its stake in  QuidelOrtho by 298.1% in the second quarter. Osaic Holdings Inc. now owns 3,300 shares of the company's stock worth $95,000 after purchasing an additional 2,471 shares during the period. 99.00% of the stock is owned by hedge funds and other institutional investors. </p><h2>QuidelOrtho Trading Up 3.1%</h2><p>QuidelOrtho stock opened at $34.34 on Thursday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 0.98 and a current ratio of 1.78. The stock has a market cap of $2.33 billion, a PE ratio of -2.02 and a beta of 0.59. The stock has a 50-day moving average of $27.44 and a two-hundred day moving average of $27.62. QuidelOrtho Corporation has a one year low of $19.50 and a one year high of $46.24. </p><p>QuidelOrtho (NASDAQ:QDEL - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.29. The firm had revenue of $699.90 million for the quarter, compared to the consensus estimate of $667.45 million. QuidelOrtho had a negative net margin of 42.53% and a positive return on equity of 5.75%. The company's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.85 earnings per share. QuidelOrtho has set its FY 2025 guidance at 2.000-2.150 EPS.  On average, research analysts anticipate that  QuidelOrtho Corporation will post 2.3 EPS for the current fiscal year. </p><h2>Insiders Place Their Bets</h2><p>In other news, CFO Joseph M. Busky acquired 4,770 shares of the business's stock in a transaction dated Monday, November 24th. The shares were acquired at an average cost of $26.06 per share, with a total value of $124,306.20. Following the completion of the acquisition, the chief financial officer owned 6,920 shares of the company's stock, valued at approximately $180,335.20. This trade represents a 221.86% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Brian J. Blaser bought 23,500 shares of the firm's stock in a transaction that occurred on Wednesday, November 19th. The shares were purchased at an average cost of $21.34 per share, with a total value of $501,490.00. Following the acquisition, the chief executive officer directly owned 29,533 shares of the company's stock, valued at approximately $630,234.22. This trade represents a 389.52% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 29,390 shares of company stock worth $657,340 over the last three months. Corporate insiders own  0.79% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>QDEL has been the topic of a number of research reports. UBS Group raised their target price on shares of QuidelOrtho from $26.00 to $31.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, November 6th. JPMorgan Chase &amp; Co. lowered their target price on QuidelOrtho from $26.00 to $22.00 and set an &#34;underweight&#34; rating for the company in a report on Friday, November 7th. Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of QuidelOrtho in a research note on Wednesday, October 8th. Citigroup  reissued a &#34;neutral&#34; rating and set a $33.00 target price (down previously from $40.00) on shares of QuidelOrtho in a research report on Tuesday, October 7th. Finally, Zacks Research cut shares of QuidelOrtho from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Monday, October 13th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and three have issued  a Sell rating to the company's stock. Based on data from MarketBeat, the company  has a consensus rating of &#34;Reduce&#34; and an average price target of $38.20.</p><p><b>View Our Latest Research Report on QuidelOrtho</b></p><h2>QuidelOrtho Profile</h2> (Free Report)<p>QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.  </p><p>The company's product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than QuidelOrtho</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>Executive Order 14330: Trump’s Biggest Yet</li><li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li></ul><p><strong>Want to see what other hedge funds are holding QDEL?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QuidelOrtho Corporation (NASDAQ:QDEL - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UURFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UURFTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in QuidelOrtho Right Now?</h2><p>Before you consider QuidelOrtho, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QuidelOrtho wasn't on the list.</p><p>While QuidelOrtho currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

QDEL

<p>Cwm LLC reduced its stake in QuidelOrtho Corporation (NASDAQ:QDEL) by 82.9% in Q3, selling 32,785 shares and retaining 6,765 shares valued at $199,000. Other institutional investors also adjusted their holdings, with significant increases from Allworth Financial LP and EverSource Wealth Advisors LLC. QuidelOrtho's stock opened at $34.34, with a market cap of $2.33 billion. The company reported $0.80 EPS for the last quarter, exceeding estimates, despite a 3.7% revenue decline year-over-year. Insiders have recently increased their ownership significantly, with CFO and CEO making notable purchases.</p>

Cwm LLC Sells 32,785 Shares of QuidelOrtho Corporation $QDEL